Abstract YO5
Case summary
Complete Response in a Metastatic Gallbladder Adenocarcinoma Patient treated with Checkpoint Inhibitor/Chemotherapy Combination: A Case Report
Gallbladder Carcinoma is a rare malignancy with an overall incidence of 3 per 100,000. Prognosis is poor with a median overall survival of 11.7 months. This is attributed to aggressive tumor biology and advanced stages at diagnosis. The standard treatment of advanced gallbladder carcinoma is gemcitabine-based combination (gemcitabine-cisplatin). Recently, the superiority of adding the immune checkpoint inhibitor durvalumab to gem/cis was shown in the TOPAZ-1 trial. This case report highlights promising results on the use of durvalumab in advance gallbladder adenocarcinoma.
This is a case of a 64-year-old male who presented with abdominal pain. CT scan of the whole abdomen revealed cholecystolithiasis with cholecystitis, intraluminal hyperdense mass, consider gallbladder malignancy. Patient underwent exploratory laparotomy with frozen section biopsy which showed peritoneal fluid positive for adenocarcinoma. Intraoperatively, the gallbladder mass was unresectable, with a post operative diagnosis of Gallbladder Adenocarcinoma Stage IV. Subsequently, the patient was treated with Durvalumab (1500mg on day 1), Gemcitabine (1000mg/m2 on days 1 and 8) and cisplatin (25mg/m2 on days 1 and 8) every 3 weeks for 8 cycles.
After 8 cycles of systemic chemotherapy, a follow-up CT scan revealed complete regression of the intraluminal gallbladder mass. PET/CT scan also showed no evidence of hypermetabolic recurrent and metastatic disease. Patient underwent resection of the gallbladder mass with pathologic findings of negative for residual tumor cells, chronic cholecystitis with mucosal erosion and chemotherapy induced histologic changes.
This case report highlights the rare but possible complete pathologic response with the use of immune checkpoint inhibitor durvalumab and gemcitabine/cisplatin combination in advanced gallbladder adenocarcinoma. This is consistent with results of the TOPAZ1 trial demonstrating promising efficacy and improved outcomes with checkpoint inhibitors.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
399P - Role of denosumab as targeted therapy in treatment of unresectable or recurrent cases of giant cell tumor of the bone
Presenter: Anchal Mishra
Session: Poster viewing 06
400P - Phase I study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma (mel)
Presenter: Omid Hamid
Session: Poster viewing 06
401P - A phase Ib study of E7386, a CREB-binding protein (CBP)/β-catenin interaction inhibitor, in combination with lenvatinib in patients (pts) with advanced solid tumors
Presenter: Shunsuke Kondo
Session: Poster viewing 06
402P - Phase I study of selumetinib in Chinese pediatric and adult patients (pts) with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN): Interim results
Presenter: Xiao-Jun Yuan
Session: Poster viewing 06
403P - Gender trend over time of principal investigators within large Australian cancer clinical trials groups
Presenter: Thi Thao Vi Luong
Session: Poster viewing 06
404P - Adolescent & young adult cancers (AYA): Experience from a large rural teaching hospital in South India
Presenter: Vishwapriya Godkhindi
Session: Poster viewing 06
405P - Evaluating medical oncology outcomes (EMOO) in Asia study: Diagnosis, staging, treatment patterns and outcome of patients with lung cancer registered 2017-2019
Presenter: Ross Soo
Session: Poster viewing 06
406P - Adrenal insufficiency induced by immune checkpoint inhibitors: Clinical characteristics of 145 cases
Presenter: kaoru koshiba
Session: Poster viewing 06
407P - A post-marketing surveillance of the real-world safety and effectiveness of avelumab in patients with curatively unresectable Merkel cell carcinoma in Japan
Presenter: Naoya Yamazaki
Session: Poster viewing 06
408P - Machine learning for glioblastoma screening from histopathology whole slide imaging
Presenter: Eva Yi Wah Cheung
Session: Poster viewing 06